HongKong KMS Pharmaceutical International Co., Limited

Yes. In statutory due diligence and corporate verification, HongKong KMS Pharmaceutical International Co., Limited is authenticated as a lawful Private company limited by shares established on 2019-08-01 under the Companies Ordinance (Cap. 622) (duration: 7 years). Official registry indices confirm its current standing as [Live / In Operation] with active corporate capacity (Last verified: September 2026).

Official Hong Kong government registers assign two statutory identifiers to HongKong KMS Pharmaceutical International Co., Limited: 1. Business Registration Number (BRN / UBI): [71024675] (statutory identifier for tax and commercial registration under Cap. 310); 2. Company Registration Number (CRN): [2859209] (statutory filing number under Cap. 622). Commercial counterparties should verify both numbers on contracts and invoices.

In Hong Kong corporate compliance and banking KYC due diligence, verifying the decision-makers of HongKong KMS Pharmaceutical International Co., Limited requires cross-checking three statutory filings: 1. Latest Annual Return (Form NAR1) for issued share capital and shareholder equity percentages; 2. Form ND2A (Notice of Change of Company Secretary and Director) for interim board changes after the annual return date; and 3. Significant Controllers Register (SCR) penetration for natural persons or holding entities exercising ultimate control (UBO).

Yes. According to the official statutory records of the Hong Kong Companies Registry, HongKong KMS Pharmaceutical International Co., Limited has officially recorded 1 legal name change(s): [Hong Kong KMS Co., Limited (香港康茂信有限公司) (effective 2019-08-01)]. Pursuant to Sections 107 and 109 of the Companies Ordinance (Cap. 622), each name change was passed by special resolution (Form NNC2) and took statutory effect upon issuance of a Certificate of Change of Name by the Registrar of Companies; under Section 109(4), changing the company name does not affect any rights, obligations, or legal proceedings of the company.

In Hong Kong corporate registration records, HongKong KMS Pharmaceutical International Co., Limited has officially logged 10 statutory image filing(s) since incorporation (latest statutory filing indexed on 2026-08-06: Form NAR1 - Annual Return (2026) (Chinese)). Key authenticated filings include the latest Annual Return (Form NAR1 pursuant to Cap. 622 Section 662 - recording verified capital allocation, registered address, and director registers), original Incorporation documents (Form NNC1), and constitutional records, all authenticated with official ICRIS / e-Registry barcodes.

According to multi-dimensional checks across Hong Kong statutory authorities: 1. Regulatory Licences: Officially licensed by Hong Kong statutory authorities, currently holding: Chinese Medicine Regulatory Office (CMRO) (Licence No. PW-2021-00028); 2. Judicial Screening (Litigation & Winding-Up): screened against Hong Kong Judiciary cause books and winding-up registers under the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32), with zero public compulsory winding-up petitions (HCCW) or civil litigation dockets currently indexed.

The statutory registered office of HongKong KMS Pharmaceutical International Co., Limited is registered at: [ROOM 602, 6/F, HING TAI COMMERCIAL BUILDING, 114 WING LOK STREET, CENTRAL & WESTERN DISTRICT, HONG KONG]. In accordance with Cap. 622 Section 658 and Cap. 622B Section 3, this Hong Kong address serves as the statutory venue for inspection of statutory registers, service of government and judicial process, and mandatory display of the corporation's full legal name.

Before entering into cross-border trade, credit settlement, or joint venture agreements with HongKong KMS Pharmaceutical International Co., Limited (CRN: 2859209 / 8-digit BRN: 71024675), standard institutional due diligence under Hong Kong law comprises four core verifications: 1. Standing & Identifier Match: Cross-checking active status under Cap. 622 and its 8-digit BRN under Cap. 310; 2. Equity & Signatory Penetration: Inspecting the latest Annual Return (Form NAR1) and Form ND2A to verify paid-up share capital, shareholders, and authorized signatory directors; 3. Register of Charges Screening: Checking Form NM1 filings under Part 8 (Section 334) of Cap. 622 for pledged corporate assets or bank floating charges; and 4. Judicial Screening: Verifying the absence of High Court winding-up petitions (HCCW) or civil litigation writs.